닥플 플러스
The 31st Symposium of Yonsei Song-Dang Institute for Cancer Research: Bridging Clinical Needs and Drug Development, Accelerating Success Through Shared Experience
연세대학교 의과대학
연수평점 :4점
오프라인
주관
연세대학교 의과대학 / 연세의생명연구원 송당암연구센터
교육일자
2026-11-05
수강료
100,000원
교육형태
오프라인
등록일시
2026-09-10
교육시간
6시간 20분
연수평점
4점
장소
서울특별시 신촌 세브란스병원 본관 6층 은명대강당
교육종류
기타
타임테이블
| 날짜 | 시간 | 강의명 | 강사 | 구분 |
|---|---|---|---|---|
| 2026-11-05 | 09:30~09:50 | Drug developments for pancreatobiliary cancers and clinical unmet needs | 이충근(연세대학교 의과대학, 연세암병원 종양내과) | - |
| 2026-11-05 | 09:50~10:10 | Breast Cancer: Unmet Clinical Needs and Lessons from Clinical Trials—A Clinician’s Perspective | 김건민(연세대학교 의과대학, 연세암병원 종양내과) | - |
| 2026-11-05 | 10:10~10:30 | Optimizing Anti-EGFR Therapy in Colorectal Cancer | 김한상(연세대학교 의과대학, 연세암병원 종양내과) | - |
| 2026-11-05 | 10:30~11:00 | Panel Discussion | 김윤미(청년의사) | - |
| 2026-11-05 | 11:00~11:20 | 휴식 | - | - |
| 2026-11-05 | 11:20~11:40 | Yuhan’s Approach to Novel Drug Development: From Candidate Selection to Clinical Entry | 최영기(유한양행) | - |
| 2026-11-05 | 11:40~12:00 | Optimization of Anticancer Drug Indications Using Machine Learning-Based ONIX | 최인영(한미약품) | - |
| 2026-11-05 | 12:00~12:20 | Strategic Approaches to Oncology Drug Development: Clinical Entry Experience and Future Development Directions | 도현미(대웅제약) | - |
| 2026-11-05 | 12:20~12:50 | Panel Discussion | 홍숙(청년의사) | - |
| 2026-11-05 | 12:50~14:10 | 휴식 | - | - |
| 2026-11-05 | 14:10~14:30 | From Unmet Clinical Needs to Better Therapies in Genitourinary Cancers: A Clinician’s Perspective on Drug Development | 신상준(연세대학교 의과대학, 연세암병원 종양내과) | - |
| 2026-11-05 | 14:30~14:50 | Unmet Needs in Lung Cancer Drug Development | 김혜련(연세대학교 의과대학, 연세암병원 종양내과) | - |
| 2026-11-05 | 14:50~15:10 | Gastric Cancer: Unmet Clinical Needs and Lessons from Drug Development | 정민규(연세대학교 의과대학, 연세암병원 종양내과) | - |
| 2026-11-05 | 15:10~15:40 | Panel Discussion | 김윤미(청년의사) | - |
| 2026-11-05 | 15:40~16:00 | 휴식 | - | - |
| 2026-11-05 | 16:00~16:20 | The combination with 4-1BB T cell engaging bispecific antibody: Enhance Tcell activation and induce durable T cell memory | 이상훈(ABL Bio) | - |
| 2026-11-05 | 16:20~16:40 | Preclinical Development of ITC-6146RO: Development Strategy and Key Considerations for a B7-H3-Targeted ADC | 전은주(IntoCell) | - |
| 2026-11-05 | 16:40~17:00 | Combining RNA Trans-Splicing with Cancer Immunotherapy: Early Clinical Experience and Future Development Strategy of RZ-001 | 홍성우(Rznomics) | - |
| 2026-11-05 | 17:00~17:20 | Target Engagement and Therapeutic Potential of FB849, an HPK1 Inhibitor, inAdvanced Solid Tumors: PK-Proportional Biomarker Inhibition and Antitumor Activity in Previously Treated Patients | 김성곤(1ST Biotherapeutics) | - |
| 2026-11-05 | 17:20~17:50 | Panel Discussion | 홍숙(청년의사) | - |
문의처
담당자
박세정
연락처
02-2228-8049
이메일
seupark@yuhs.ac